Adolor draws FDA rebuke for rep downplaying Entereg REMS
This article was originally published in Scrip
Executive Summary
An Adolor representative's comments downplaying the reason behind the risk evaluation and mitigation strategy (REMS) for the bowel drug Entereg (alvimopan) have drawn a violation letter from the US FDA.